Seasonal Influenza Global Market Report 2025

The seasonal influenza market size has grown rapidly in recent years. It will grow from $8.41 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to the rising prevalence of influenza, the increasing elderly population, the growing prevalence of infectious and chronic diseases, the rising burden of influenza-related illness, and the surge in respiratory infections.

The seasonal influenza market size is expected to see rapid growth in the next few years. It will grow to $18.55 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to the increasing demand for oral drug solutions, expanding research and development activities, rising vaccination rates, improving healthcare infrastructure, and the growing demand for retail pharmacies. Major trends include advancements in treatment options, technological innovations, progress in vaccine development, the adoption of mRNA technology, and the integration of digital health solutions for monitoring and diagnosis.

The rising prevalence of respiratory infections is expected to drive the growth of the seasonal influenza market in the coming years. Respiratory infections, caused by viruses or bacteria, affect the respiratory system, including the sinuses, throat, airways, and lungs. Several factors contribute to the increasing prevalence of these infections, including air pollution, climate changes, weakened immune responses, and the ease of viral transmission in crowded or poorly ventilated areas. Seasonal influenza treatments play a crucial role in preventing or reducing the severity of respiratory infections by targeting the influenza virus and managing symptoms that may lead to secondary infections. For example, in October 2024, the UK Health Security Agency reported a 10.7% year-over-year increase in tuberculosis (TB) cases in England, rising from 4,380 cases in 2022 to 4,850 cases in 2023. As a result, the rising incidence of respiratory infections is expected to drive the expansion of the seasonal influenza market.

Leading companies in the seasonal influenza market are advancing treatment options through innovations such as combination vaccines, which enhance immunity by targeting multiple strains of the virus, improving effectiveness, and reducing the need for frequent vaccinations. Combination vaccines offer protection against multiple diseases or viral strains with a single injection, minimizing the number of shots required for immunization. For instance, in October 2023, Moderna, Inc., a US-based biotechnology company, announced positive interim Phase 1/2 trial results for mRNA-1083, an investigational combination vaccine designed to protect against both influenza and COVID-19. Developed to enhance compliance, streamline administration, and improve convenience for individuals and healthcare systems, mRNA-1083 is being evaluated for safety and immunogenicity in comparison to standard flu vaccines Fluarix (for individuals aged 50-64) and Fluzone HD (for individuals aged 65-79), as well as against the Spikevax booster.

In February 2023, Clover Biopharmaceuticals Ltd., a China-based commercial-stage biotechnology company, partnered with Adimmune Corporation to distribute AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for individuals aged three and older in mainland China. Adimmune Corporation is a Taiwan-based company specializing in vaccine development and production.

Major players in the seasonal influenza market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc, Merck KGaA, Moderna Inc., Boehringer Ingelheim International GmbH, Sinovac Biotech Ltd., Daiichi Sankyo Company Limited, CSL Limited, Genentech Inc., Shionogi & Co. Ltd., Emergent BioSolutions Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Bharat Biotech International Limited, Vaxart Inc., Inovio Pharmaceuticals Inc., SK bioscience Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., Altimmune Inc.

North America was the largest region in the seasonal influenza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in seasonal influenza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the seasonal influenza market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Seasonal influenza, commonly known as the flu, is a contagious respiratory infection caused by influenza viruses that circulate worldwide, primarily during specific seasons (typically fall and winter in temperate regions). It spreads through respiratory droplets when an infected person coughs, sneezes, or talks. Seasonal influenza causes widespread illness and can lead to severe complications, particularly in vulnerable populations such as the elderly and individuals with weakened immune systems.

The primary types of seasonal influenza include influenza A, B, C, and D viruses. Influenza A virus is a subtype that infects humans and various animals, often responsible for seasonal flu outbreaks and pandemics. Treatments are administered through different routes, including parenteral, oral, and other methods. These treatments are distributed through various channels, such as hospitals, government and institutional supply, pharmacies, and online platforms. Treatment options include antivirals, neuraminidase inhibitors, vaccinations, and other therapeutic approaches.

The seasonal influenza market research report is one of a series of new reports that provides seasonal influenza market statistics, including the seasonal influenza industry global market size, regional shares, competitors with the seasonal influenza market share, detailed seasonal influenza market segments, market trends, and opportunities, and any further data you may need to thrive in the seasonal influenza industry. This seasonal influenza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The seasonal influenza market consists of revenues earned by entities by provide services such flu vaccination services, specialized care for high-risk populations, telemedicine services, and proactive treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The seasonal influenza market consists of sales of medications, diagnostic kits, preventive and supportive products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.